1. Japan Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Nihon Kohden Corporation

Nihon Kohden Corporation

NHNKF
Nihon Kohden CorporationUS flagOther OTC
15.07
USD
- -
- -
2.41BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
754.24
871.8
915.12
945.3
970.64
1,017.6
1,049.83
1,086.3
1,172.59
1,210.1
1,227.28
1,319.74
1,357.09
706.68
Basic EPS, GAAP
52.08
70.26
63.41
60.06
53.4
53.46
65.71
57.86
107.1
138.25
101.64
101.22
84.87
53.87
Free Cash Flow per Basic Share
59.87
27.8
46.45
18.96
26.56
43.96
38.57
33.03
62
134.3
-63.97
64.33
39.59
21.39
Dividend per Share
11.24
14.96
18.79
17.29
17.49
17.5
17.51
17.5
17.49
28.56
34.06
35.48
30.7
15.05
Book Value per Share
384.05
439.31
483.04
521.86
569.29
605.51
645.53
681.56
771.09
883.51
950.86
1,017.35
1,045.79
969.96
Tangible Book Value per Share
397.09
465.82
526.51
522.43
573.73
608.94
654.82
690.65
802.29
900.47
970.53
1,047.71
924.93
1,021.26
Basic Weighted Avg Shares
176
176
176
175
171
171
170
170
170
170
168
168
166
168
Sales/Revenue/Turnover
132,538
153,194
160,803
165,522
166,285
174,249
178,799
185,007
199,727
205,129
206,603
221,986
225,424
118,450
Operating Margin (%)
10.17
11.45
9.9
9.93
8.17
8.33
8.41
8.38
13.57
15.11
10.22
8.83
9.19
10.22
Depreciation Expense
2,909
3,240
3,605
3,624
3,564
3,486
3,692
3,745
4,543
3,490
3,791
3,853
4,190
2,169
Net Income, GAAP
9,151
12,346
11,142
10,516
9,149
9,154
11,191
9,854
18,243
23,435
17,110
17,026
14,098
9,029
Effective Tax Rate (%)
36.96
34.98
36.02
33.84
33.95
34.39
27.88
29.51
32.84
31.6
30.77
42.02
34.64
46.33
Profit Margin (%)
6.9
8.06
6.93
6.35
5.5
5.25
6.26
5.33
9.13
11.42
8.28
7.67
6.25
7.62
Working Capital
56,153
65,267
72,735
70,028
74,229
76,086
83,865
88,701
105,532
121,071
125,932
134,432
110,789
127,799
LT Debt
28
31
30
29
16
17
17
42
43
24
17
39
38
- -
Total Equity
76,254
88,508
99,301
97,669
103,885
109,352
116,086
121,773
138,983
156,378
167,602
181,080
181,292
176,381
Return on Invested Capital (%)
11.15
13.02
10.38
10.68
8.64
8.71
9.35
8.93
13.39
13.69
8.77
6.34
6.79
3.61
Return on Capital (%)
14.07
16.76
13.58
11.78
9.63
9.06
10.44
8.69
14.7
16.63
11.02
10.26
7.6
5.51
Return on Common Equity (%)
14.32
17.07
13.75
11.93
9.69
9.1
10.48
8.72
14.75
16.67
11.04
10.28
8.18
5.52

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
615
- -
477
LT Borrowings
- -
- -
- -
LT Finance Leases
39
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
168
- -
167
Market Capitalization
299,403
395,293
363,081

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
184,333
- -
167,891
Cash, Cash Equivalents & STI
50,432
- -
49,057
Accounts Receivable, Net
68,014
- -
57,035
Inventories
57,786
- -
55,949
Total Current Liabilities
49,901
- -
40,092
Payables & Accruals
- -
- -
- -
ST Debt
615
- -
477
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.3%
8.4%
0.12%
Free Cash Flow
-16.76%
-36.75%
-39.22%
Net Income, GAAP
6.06%
13.78%
-17.2%
Sales/Revenue/Turnover
3.46%
4.08%
1.55%
Total Cash Common Dividend
6.06%
14.09%
-14.54%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
48,728
54,808
52,633
65,817
221,986
2025
- -
- -
- -
- -
225,424
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22.51
- -
- -
- -
101.22
2025
- -
- -
- -
- -
84.87
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
20.18
- -
- -
- -
35.48
2025
- -
- -
- -
- -
30.7
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Hirokazu Ogino
Full Time Employees
5,891
Sector
Healthcare
Industry
Medical - Devices
Address
1-31-4 Nishiochiai Shinjuku Japan 161-8560
IPO Date
Feb 18, 2020
CIK
0001543726
Website
nihonkohden.com
Similar Companies
Implanet S.A. (ALIMP.PA)
SHL Telemedicine Ltd. (0QMX.L)
Talis Biomedical Corporation (TLIS)
Neovasc Inc. (NVCN.TO)
Senzime AB (publ) (SNZZF)
Shanghai Sanyou Medical Co., Ltd. (688085.SS)
Business
Nihon Kohden Corporation, founded in 1951 and headquartered in Tokyo, Japan, develops, manufactures, sells, and maintains medical electronic equipment and related systems for clinical areas including emergency response, testing, diagnosis, treatment, and rehabilitation. The company's core products encompass electroencephalographs, electrocardiographs, evoked potential and electromyography measuring instruments, polygraphs for cath-labs, patient monitors measuring vital signs such as ECG, SpO2, and NIBP, defibrillators including biphasic automated external defibrillators for hospitals, ambulances, and public use; imported treatment devices like pacemakers, implantable cardioverter defibrillators, and in-house ventilators launched in fiscal 2019; laboratory equipment such as blood cell counters, reagents, and clinical chemistry analyzers for C-reactive protein and HbA1c; plus IT systems including diagnostic information systems for laboratories and clinical information systems for operating rooms, intensive care, and general wards. Nihon Kohden operates globally across more than 120 countries and regions, with subsidiaries in the United States, Europe, and Asia, and maintains a leading worldwide market share in electroencephalographs essential for epilepsy, brain tumors, and sleep disorders. In late 2024, the company acquired a 71.4% stake in NeuroAdvanced Corp., parent of Ad-Tech Medical, for approximately 16 billion yen to expand its neurology portfolio with specialized intracranial electrodes, enhancing solutions for drug-resistant epilepsy while Archimed retains a minority joint venture stake; additionally, in 2024 it announced a 10 billion yen share buyback program through March 2025 and implemented a two-for-one stock split effective July 1, 2024.

Company News

APIChat

  • businesswire.com

    Nihon Kohden Brings Advanced EEG Technology Built on 70 Years of Innovation to Booth #725 at the American Epilepsy Society 2025 Annual Meeting